These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 38263984)

  • 1. Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies.
    Wong RS; Ong RJ; Lim JS
    Cancer Drug Resist; 2023; 6(4):768-787. PubMed ID: 38263984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Immunotherapies to Overcome Intrinsic Resistance to Checkpoint Blockade in Microsatellite Stable Colorectal Cancer.
    Kim CW; Chon HJ; Kim C
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
    Wang Q; Shen X; Chen G; Du J
    Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
    Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
    Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape.
    Uliano J; Nicolò E; Corvaja C; Taurelli Salimbeni B; Trapani D; Curigliano G
    Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1399-1413. PubMed ID: 36317756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in immune therapies for the treatment of microsatellite instability‑high/deficient mismatch repair metastatic colorectal cancer (Review).
    Choucair K; Radford M; Bansal A; Park R; Saeed A
    Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34396449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
    Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
    Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers.
    Ruiz-Bañobre J; Goel A
    Gastroenterology; 2019 Mar; 156(4):890-903. PubMed ID: 30578781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding resistance to immune checkpoint inhibitors in advanced breast cancer.
    Tarantino P; Barroso-Sousa R; Garrido-Castro AC; McAllister SS; Guerriero JL; Mittendorf E; Curigliano G; Tolaney SM
    Expert Rev Anticancer Ther; 2022 Feb; 22(2):141-153. PubMed ID: 34919490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
    Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of immune checkpoint inhibitors in colorectal cancer.
    Wang L; Huang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions.
    Zhang C; Zhang C; Wang H
    Cancer Lett; 2023 May; 562():216182. PubMed ID: 37076040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.
    Kreidieh M; Mukherji D; Temraz S; Shamseddine A
    Biomed Res Int; 2020; 2020():9037217. PubMed ID: 32090113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
    Tan E; Sahin IH
    Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
    [No Abstract]   [Full Text] [Related]  

  • 15. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
    Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
    Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cutting-edge progress of immune-checkpoint blockade in lung cancer.
    Zhou F; Qiao M; Zhou C
    Cell Mol Immunol; 2021 Feb; 18(2):279-293. PubMed ID: 33177696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of treatment with immune checkpoint inhibitors for gastrointestinal, hepatobiliary, and pancreatic cancers.
    Eso Y; Seno H
    Therap Adv Gastroenterol; 2020; 13():1756284820948773. PubMed ID: 32913444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired.
    Marei HE; Hasan A; Pozzoli G; Cenciarelli C
    Cancer Cell Int; 2023 Apr; 23(1):64. PubMed ID: 37038154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.
    Jia Y; Liu L; Shan B
    Ann Transl Med; 2020 Sep; 8(17):1095. PubMed ID: 33145314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions.
    Chen JT; Zhou YW; Han TR; Wei JL; Qiu M
    Front Immunol; 2023; 14():1269341. PubMed ID: 38022667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.